



09-15-04

Attorney's Docket No.: 16596-018001

1642
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Matthew C. Coffey, et al. Art Unit : 1642
Serial No. : 10/076,074 Examiner : Sheela J. Huff
Filed : February 15, 2002
Title : SENSITIZATION OF CHEMOTHERAPEUTIC AGENT RESISTANT
 NEOPLASTIC CELLS WITH A VIRUS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Copies of the disclosed references are attached herewith.

1. Steele, T. A. and Cox, D. C., "Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporin", Cancer Biotherapy 10(4): 307-315 (1995).
2. Rayter, S. I. et al., "p21^{ras} mediates control of IL-2 gene promoter function in T cell activation", EMBO Journal 11(12): 4549-4556 (1992).
3. Baldari, C. T., et al., "Interleukin-2 promoter activation in T-cells expressing activated Ha-ras", J. Biological Chemistry 267(7): 4289-4291 (1992).
4. Umezawa K. et al., "Isolation of a new vinca alkaloid from the leaves of *Ervatimia microphylla* as an inhibitor of *ras* functions", Anticancer Research 14: 2413-2418 (1994).
5. Umezawa K. et al., "Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice", Drugs Exptl. Clin. Res. 22(2): 36-40 (1996).

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV 321 388 990 US

September 13, 2004
Date of Deposit

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. Pursuant to 37 U.S.C. § 1.97 (c)(2), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

While this information disclosure statement may contain "material" information pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" to the invention disclosed and claimed in the above-referenced application unless specifically designated as such.


Applicants specifically reserve the right, where appropriate, to antedate any reference listed herein by the appropriate showing under 37 C.F.R. § 1.131 and § 1.608, or any other appropriate means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.


Should it be determined that additional fees or a credit is due, please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Sept. 13, 2004


Steven G. Bacsi
Reg. No. 50,736

Fish & Richardson P.C.
500 Arguello Street, Suite 500
Redwood City, California 94063
Telephone: (650) 839-5070
Facsimile: (650) 839-5071

 Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce, Patent and Trademark Office	Attorney's Docket No. 16596-018001	Application No. 10/076,074
	Information Disclosure Statement by Applicant (Use several sheets if necessary)		
	Applicant Matthew C. Coffey, et al.		Filing Date February 15, 2002

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AI							
	AJ							
	AK							
	AL							
	AM							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AN	Steele, T. A. and Cox, D. C., "Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporin", Cancer Biotherapy 10(4): 307-315 (1995).
	AO	Rayter, S. I. et al., "p21 ^{ras} mediates control of IL-2 gene promoter function in T cell activation", EMBO Journal 11(12): 4549-4556 (1992).
	AP	Baldari, C. T., et al., "Interleukin-2 promoter activation in T-cells expressing activated Ha-ras", J. Biological Chemistry 267(7): 4289-4291 (1992).
	AQ	Umezawa K. et al., "Isolation of a new vinca alkaloid from the leaves of <i>Ervatimia microphylla</i> as an inhibitor of <i>ras</i> functions", Anticancer Research 14: 2413-2418 (1994).
	AR	Umezawa K. et al., "Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice", Drugs Exptl. Clin. Res. 22(2): 36-40 (1996).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	